NASDAQ:BLRX

BioLineRx Stock Forecast, Price & News

$3.25

-0.01 (-0.31 %)

(As of 07/30/2021 12:56 PM ET)

Add

Compare

Today's Range

$3.23

▼

$3.29

50-Day Range

$2.67

▼

$3.35

52-Week Range

$1.40

▼

$6.34

Volume4,345 shs

Average Volume3.45 million shs

Market Capitalization$153.52 million

P/E RatioN/A

Dividend YieldN/A

Beta2.09

30 days | 90 days | 365 days | Advanced Chart

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

About BioLineRx

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd. American Depositary Shares (BLRX)
July 27, 2021 | nasdaq.com

-$0.12 Earnings Per Share Expected for BioLineRx Ltd. (NASDAQ:BLRX) This Quarter
July 10, 2021 | americanbankingnews.com

BioLineRx: A Top Candidate For A Takeover Before 2022 Ends - Seeking Alpha
June 30, 2021 | seekingalpha.com

Is Bioline RX Ltd (BLRX) A Good Stock To Buy?
June 30, 2021 | finance.yahoo.com

New Strong Sell Stocks for June 4th - Yahoo Finance
June 4, 2021 | finance.yahoo.com

BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 26, 2021 | finance.yahoo.com

BioLineRx to Report First Quarter 2021 Results on May 26, 2021 - Yahoo Finance
May 20, 2021 | finance.yahoo.com

BioLineRx to Report First Quarter 2021 Results on May 26, 2021
May 20, 2021 | finance.yahoo.com

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients - Yahoo Finance
May 4, 2021 | finance.yahoo.com

BioLineRx Stock Is Trading Higher As Motixafortide-G-CSF Combo Shows Promise In Transplant Setting For Multiple Myeloma Patients
May 4, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
Previous Symbol
CUSIPN/A
CIK1498403
Webwww.biolinerx.com
Phone972-8642-9100
Employees38
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.68 per share
Price / Book4.78

Profitability

EPS (Most Recent Fiscal Year)($1.80)
Net Income$-30,020,000.00
Net MarginsN/A
Return on Equity-95.42%
Return on Assets-58.40%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares47,237,000
Market Cap$153.52 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.59 out of 5 stars

Medical Sector

865th out of 2,216 stocks

Pharmaceutical Preparations Industry

421st out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
BioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.50, BioLineRx has a forecasted upside of 342.1% from its current price of $3.28.
Amount of Analyst Coverage
BioLineRx has only been the subject of 1 research reports in the past 90 days.

3.8 Community Rank

Outperform Votes
BioLineRx has received 494 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BioLineRx has received 151 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BioLineRx has received 76.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BioLineRx and other stocks. Vote “Outperform” if you believe BLRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BioLineRx does not currently pay a dividend.
Dividend Growth
BioLineRx does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioLineRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.10% of the stock of BioLineRx is held by insiders.
Percentage Held by Institutions
Only 10.47% of the stock of BioLineRx is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for BioLineRx are expected to grow in the coming year, from ($0.73) to ($0.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioLineRx is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioLineRx is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BioLineRx has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

BioLineRx (NASDAQ:BLRX) Frequently Asked Questions

Is BioLineRx a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx or view top-rated stocks.

What stocks does MarketBeat like better than BioLineRx?

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioLineRx?

BioLineRx saw a drop in short interest in July. As of July 15th, there was short interest totaling 81,800 shares, a drop of 27.2% from the June 30th total of 112,300 shares. Based on an average trading volume of 5,620,000 shares, the days-to-cover ratio is presently 0.0 days.
View BioLineRx's Short Interest.

When is BioLineRx's next earnings date?

BioLineRx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLineRx.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) issued its quarterly earnings data on Wednesday, May, 26th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.12.
View BioLineRx's earnings history.

How has BioLineRx's stock price been impacted by Coronavirus (COVID-19)?

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLRX shares have increased by 103.1% and is now trading at $3.25.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for BLRX?

2 brokers have issued 12 month target prices for BioLineRx's shares. Their forecasts range from $10.00 to $19.00. On average, they anticipate BioLineRx's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 346.2% from the stock's current price.
View analysts' price targets for BioLineRx or view top-rated stocks among Wall Street analysts.

Who are BioLineRx's key executives?

BioLineRx's management team includes the following people:

Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA, Chief Exec. Officer (Age 61, Pay $555k)
Ms. Mali Zeevi CPA, CPA, Chief Financial Officer (Age 45, Pay $314k)
Dr. Ella Sorani, Chief Devel. Officer (Age 53, Pay $357k)
Dr. Abi Vainstein-Haras, Chief Medical Officer (Age 46, Pay $347k)
Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 69)
Ms. Liron Shemesh-Darvish M.B.A., Ph.D., Sr. Director & Head of Preclinical Devel.
Ms. Jael Birenberg M.Sc., Sr. Director & Head of RA, QA and PhV
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B., Head of BD & Strategic Advisor
Mr. Raziel Fried, Treasurer & Budgetary Control Director
Dr. Leah N Klapper, Consultant (Age 56)

Who are some of BioLineRx's key competitors?

Some companies that are related to BioLineRx include Praxis Precision Medicines (PRAX), Eagle Pharmaceuticals (EGRX), Zomedica (ZOM), Cara Therapeutics (CARA), Catalyst Pharmaceuticals (CPRX), Gossamer Bio (GOSS), Evolus (EOLS), Chimerix (CMRX), Intercept Pharmaceuticals (ICPT), DiaMedica Therapeutics (DMCAF), Chinook Therapeutics (KDNY), Verastem (VSTM), Albireo Pharma (ALBO), Veru (VERU) and Marinus Pharmaceuticals (MRNS).
View all of BLRX's competitors.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

How do I buy shares of BioLineRx?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $3.25.

How much money does BioLineRx make?

BioLineRx has a market capitalization of $153.52 million. The biotechnology company earns $-30,020,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does BioLineRx have?

BioLineRx employs 38 workers across the globe.

What is BioLineRx's official website?

The official website for BioLineRx is www.biolinerx.com.

Where are BioLineRx's headquarters?

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here